Rgfp966

Chr (purity ≥ 99%) was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). LPS (055:B5), the HMGB1 antagonist sodium butyrate (SB), and the HDAC3 antagonist RGFP966 were obtained from MedChemExpress (New Jersey, United States). Dexamethasone (DEX) was purchased from Shanghai Winherb Medical Technology Co., Ltd. (Shanghai, China). TNF-α, IL-6, IL-1β, and HMGB1 enzyme-linked immunosorbent assay (ELISA) kits were purchased from Multi Sciences Biotech Co. Ltd. (Hangzhou, China). Malondialdehyde (MDA), myeloperoxidase (MPO), and superoxide dismutase (SOD) kits were purchased from the Jiancheng Bioengineering Institute (Nanjing, China). Dual-Luciferase^® reporter assay kits were purchased from Promega (Madison, WI, United States). Antibodies against HMGB1 (#6893), HDAC3 (#3949), TNF-α (#11948), IL-1β (#12703), IL-6 (#12912), inhibitor of nuclear factor kappa B (IκBα) (#4814), acetylated-lysine (#9441), NF-κB p65 (#8242), β-actin (#4970), lamin B (#13435), phospho-p65 (#3031), and phospho-IκBα (#2859) were purchased from Cell Signaling Technology (Danvers, MA, United States). All reagents used for cell culture were obtained from Gibco (Grand Island, NY, United States).

Primary HAEC were purchased from the American Type Culture Collection (Catalog No. PCS-100-011, Lot no. 63233442, Manassas, VA) and maintained in Endothelial Growth Medium-2 (Lonza) supplemented with 10% FBS (GIBCO). HDAC inhibitor Romidepsin (HY-15149), RGFP966 (HY-13909) and PCI-34051 (HY-15224), HDAC activator ITSA-1 (HY-100508) and DNMT inhibitor Decitabine (5-Aza-2'-deoxycytidine, DCA, HY-A0004) were products of MedChemExpress. Unless otherwise indicated, HAEC up to passage 10 without serum starvation were pretreated with Romidepsin (40 nM) for 1 h and then stimulated with 0.1 ng/mL TNFα (R&D Systems) for 2 h for mRNA measurement, or for 4 h for Western blot and flow cytometry analyses.